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Abstract 
Sigma receptors are usually classified as a separate class of intracellular receptors. Among them the sigma-1 receptor has 
been the most studied regarding its pharmacological applications. This receptor with average or high affinity binds a wide 
range of chemical compounds of very different structural classes and a variety of therapeutic and pharmacological properties. 
The sigma-1 receptor is a trans-membrane protein placed in the endoplasmic reticulum (ER), which regulates the function 
of inositol-3-phosphate receptor, stabilizing the calcium signaling between ER and mitochondria. There are studies that the 
sigma-1 receptor is involved in the formation of many neurological and psychiatric conditions. It is assumed that the sigma-1 
receptor acts as a sensor of normal calcium operation. The studies over the recent years have shown the role of the violation in 
calcium signaling in the pathogenesis of Alzheimer’s and Huntington’s diseases. In particular, changes in calcium homeostasis 
of the endoplasmic reticulum lead to the break of synaptic connections in the neurons. Thus, the sigma-1 receptor holds 
promise in application as a potential therapeutic target for the treatment of neuropathological diseases. 
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Numerous data of preclinical studies performed on
various models of memory impairment indicates that
agonists of sigma-1 receptors show much promise as
drugs to treat cognitive dysfunction [1,2,20,61–63] .
Adjusting the excitability of the neuronal plasma
membrane through the sigma-1 receptor probably
plays a key role in preventing neurologic diseases. ction and hosting by Elsevier B.V. This is an open access article 
c-nd/4.0/ ). 
. 
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sigma-1 receptor acts as an intracellular modulator: 
between the endoplasmic reticulum (ER) and the 
mitochondria, 
between the ER and the cell nuclei, 
between the ER and the membrane, 
as well as a modulator of intracellular signaling. 
Since the sigma-1 receptor binds a wide range 
of chemical compounds of very different structural 
classes with various therapeutic properties, it is of 
great interest for pharmacology. The researchers of the 
Laboratory of Molecular Neurodegeneration (LMN) of 
the Peter the Great St. Petersburg Polytechnic Univer- 
sity support the calcium hypothesis of neuropathol- 
ogy. This hypothesis indicates that the disruption of 
calcium signaling plays a key role in the emergence 
and development of neurodegenerative diseases. The 
sigma-1 receptor, which is the subject of this review, 
regulates the function of the inositol trisphosphate re- 
ceptor, thus stabilizing calcium signaling between mi- 
tochondria and the endoplasmic reticulum. 
Consequently, our greatest interest in studying the 
sigma-1 receptor is in revealing its biophysical role 
in forming neurological and psychiatric conditions, as 
well as in regulating intracellular concentrations of 
calcium ions and calcium signaling. 
The purpose of this review is to analyze the infor- 
mation in the current literature regarding the sigma-1 
receptor, its structure and biophysical role in cells, and 
the participation of this receptor in normal and patho- 
logical processes. 
Sigma receptors were originally considered a type 
of opioid receptors, but now they are classified as a 
separate class of receptors with unique structure and 
the set of binding ligands. Among this type of recep- 
tors, the sigma-1 receptor is the most pharmacologi- 
cally studied. 
The sigma-1 receptor has a protective function in 
different tissues. The effect of this receptor is me- 
diated by regulation of cell metabolism, suggesting 
its involvement in various neuropsychiatric diseases 
[1] . These receptors regulate various ion channels, 
including potassium, calcium, chlorine, and NMDA- 
receptors, release various neurotransmitters, provide 
lipid transport and brain-derived neurotrophic factor 
(BDNF) signaling, myelination, neurito- and synap- 
togenesis, which shows high therapeutic potential for 
the sigma-1 receptor ligands. The modulating effect 
of sigma-1 receptors on neurotransmitter systems in- 
cludes enhancing the glutamatergic, cholinergic, and 
serotoninergic neurotransmission. In contrast, the ac- tivation of sigma-1 receptors reduces the intensity of 
noradrenaline release and gamma-aminobutyric acid. 
An increase or a decrease of the calcium current due 
to the effect of sigma-1 receptors explains why the 
selective agonists of these receptors can modulate a 
wide range of neuronal effects, including a key mech- 
anism by which sigma-1 receptors influence learning 
and memory processes [2] . 
Molecular biology of the sigma-1 receptor 
This receptor is a highly conserved mammalian 
protein [3,4] . Sequence alignment showed that the pro- 
tein sequence is 30% identical (the homology is 67%) 
to yeast C8-C7 sterol isomerase, but the receptor itself 
does not exhibit this enzymatic activity [5] . 
The gene of the sigma-1 receptor is located on 
chromosome 9p13, known due to its being associ- 
ated with psychotic disorders [6] . The sigma-1 re- 
ceptor, with its small size (223 amino-acid residue), 
binds with medium or high affinity to a wide range 
of chemical compounds of very different structural 
classes with various pharmacological and therapeu- 
tic properties. Among its ligands there are such com- 
pounds as benzomorphans (SKF-10047, pentazocine, 
dextromethorphan), antipsychotics (haloperidol), an- 
tidepressants (fluvoxamine), steroids (progesterone), 
antihistamines (chlorpheniramine), nuclear hormone 
receptor ligands (tamoxifen), Са 2 + channel antagonists 
(verapamil, emopamil), antifungals (fenpropimorph, 
tridemorph) and drugs of abuse (methamphetamine, 
cocaine, and N,N-dimethyltryptamine) [7] . However, 
the sigma-1 receptor knockout mice are viable as well 
as fertile, and do not exhibit any apparent changes in 
the phenotype except for a reduced hypermotor activ- 
ity in response to SKF-10047 stimulation compared 
to wild-type mice. This fact supports the idea that the 
sigma-1 receptor is involved in response to psychos- 
timulatory actions [8] . 
Sigma-1 receptors are widely spread in the central 
nervous system, liver, kidneys, and lungs, in the en- 
docrine, immune and reproductive tissues [9] . This re- 
ceptor is a transmembrane protein specifically located 
in ceramide- and cholesterol-rich lipid microdomains 
associated with the mitochondria of the ER membrane. 
It regulates the function of the inositol-3-phosphate re- 
ceptor, stabilizing calcium signaling between the ER 
and the mitochondrion. It has been shown that the 
sigma-1 receptor forms Са 2 + -regulating trimeric com- 
plex with ankyrin-B and the inositol-3-phosphate re- 
ceptor in NG-108 neuroblastoma cells [10] . 
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 Additionally, by adjusting the levels of reactive
oxygen species, the sigma-1 receptor controls the lev-
els of Rac GTPase in the plasma membrane, thus
responsible for the formation of spines in the hip-
pocampus, which is a central brain region responsible
for memory formation [11] . Through regulating the
level of reactive oxygen species the sigma-1 receptor
also activates NF- κB transcription factor, which con-
trols the expression of the Bcl-2 anti-apoptotic pro-
tein [7] , and is therefore involved in supporting neu-
ronal life. It was demonstrated on cortical cell cultures
that SA4503, a sigma-1 receptor agonist, increased the
number of surviving cells following oxidative stress
through the suppression of the MAP kinase pathway
and the expression of glutamate receptors [12] . 
Even though the sigma-1 receptor does not directly
interact with the G-protein [13] , physical and func-
tional connections have been revealed between the
sigma-1 receptor and the cloned opioid μ-receptor
(which binds the G-protein) [14] . These interactions,
which occur only in a form of the sigma-1 receptor
related to the antagonist, manifested as significantly
facilitated activation of the G-protein by the agonist
of μ-receptor DAMGO, which is confirmed by the
enhancement (observed in vivo) of morphine-induced
analgesia by the antagonists of the sigma-1 receptor. 
Functional activity and location of the sigma-1 re-
ceptor in a cell depend on the state of the cell, on the
stimulation of the receptor by ligands and the level of
calcium concentration in the ER. The sigma-1 recep-
tor may be both active and inactive. The most recent
studies indicate that this receptor interacts with chaper-
ones, and is itself an ER chaperone [3] . When inactive
or stimulated by antagonists (for example, NE-100 or
haloperidol), the sigma-1 receptor is linked to another
ER protein, a BiP chaperone [10] . When stimulated
by agonists (for example, cocaine or pentazocine) at a
saturation concentration, or if subjected to prolonged
cellular stress caused by, for example, hypoglycemia
or depletion of calcium reserves in the ER under the
action of thapsigargin, the sigma-1 receptor translo-
cates either to ER regions near to the plasma mem-
brane, or directly into the plasma membrane [15, 16] .
Overexpression of the sigma-1 receptor also leads
to its increased translocation to the plasma membrane
[17] . It was demonstrated in a mouse model [18] that
chronic alcohol consumption causes increased ex-
pression (and therefore, possibly, translocation to the
plasma membrane) of the sigma-1 receptor in the
brain. At the same time, a recent study by Yao et
al. [19] has revealed that cocaine causes the sigma-1
receptor to translocate from the ER to the lipid raftsof the plasma membrane, where chemokines CCL2
are induced in microglia via Src-kinase activation. It
is also shown that overexpression of the sigma-1 re-
ceptor in cortical neurons increases the binding of the
tyrosine kinase receptor B and phospholipase C [20] . 
After translocating to the plasma membrane, the
sigma-1 receptor interacts with various ion channels,
receptors and kinases [21] . In fact, it was demon-
strated using the patch-clamp on pituitary gland cells
that pentazocine, which is a sigma-1 receptor agonist,
inhibits the outward current of potassium ions (K + ),
and this phenomenon can be reversed by the sigma-1
receptor antagonist NE-100 [22] . In addition to direct
physical interaction and regulation of the activity of
voltage-gated K + channels in mouse nerve terminals
of the posterior lobe of the pituitary gland [23] , the
sigma-1 receptor regulates the activity of the K + chan-
nel in rat hippocampal slices, intracardiac neurons and
cancer cells [24] . The sigma-1 receptor ligands mod-
ulate several types of presynaptic Са 2 + channels in
rat sympathetic and parasympathetic neurons [25] . The
sigma-1 receptor also modulates the NMDA receptor
activity [26] and affects synaptic plasticity through the
small-conductance Са 2 + -activated K + channels [27] .
The sigma-1 receptor has been shown to modulate
cardiac voltage-gated Na + channels in HEK293 and
COS- cells, as well as in neonatal mouse cardiomy-
ocytes [28] . SKF-10047, a sigma-1 receptor agonist,
inhibits calcium ion currents in cultured retinal gan-
glion cells. Direct association between the sigma-1 re-
ceptor and the L-type Ca 2 + -channel was performed
using immunoprecipitation [29] . 
There is also data indicating that the sigma-1 re-
ceptor regulates neurotransmitter release in dopamin-
ergic, serotonergic and cholinergic transmission, and
is involved in cell differentiation, cellular responses to
inflammation, and in pathogenesis of extrapyramidal
disorders [21] . 
Interestingly, the sigma-1 receptor was detected in
the extracellular space of NG-108 cells exposed to co-
caine, indicating that the receptor possibly acts as a
chaperone in the extracellular space [7] . 
The structure of the sigma-1 receptor 
The sigma-1 receptor is an integral membrane re-
ceptor, and it is predominantly localized in the ER
membranes associated with mitochondria [16] . 
Even though the detailed atomic structure of the
receptor has not yet been determined, a number of
studies have been focused on establishing the protein
topology and on mapping its active site. Initially, the
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Fig. 1. Topological models of the sigma-1 receptor, constructed on the basis of the amino acid sequence of the receptor using a variety of 
predictive algorithms: TM Pred [31] , TMHMM [32, 33] , HMMTOP [34] , MEMSAT [35] , SO SUI [36] PHOBIUS [37] , and the NMR method. 
H 2 N and COOH are, respectively, the N- and the C-terminals of the amino acid sequence; the numbers correspond to the serial numbers of 
amino acid residues; arrows indicate the orientation of the transmembrane helix in the biological membrane ( → away from the cytoplasm, 
← towards the cytoplasm) (see Fig. 2 ). sigma-1 receptor has been characterized as a type I 
transmembrane protein with a single transmembrane 
domain [30] . Currently, a fairly large number of exper- 
imental data indicates that there are two alpha-helical 
transmembrane domains. This data was obtained via 
bioinformatic analysis, molecular simulation, epitope 
mapping techniques, limited proteolysis, and NMR 
spectroscopy. 
The number and localization of transmembrane 
domains are different and depend on the specific 
algorithm chosen for predicting hydrophobic domains 
based on the amino acid sequence ( Fig. 1 ) [31–37] . 
Most algorithms indicate the presence of two or three 
hydrophobic regions (see. Fig. 1 ). The first two do- 
mains have been identified as highly ordered trans- 
membrane alpha-helices (TM1, TM2). The second 
transmembrane helix has amphipathic properties [38] . 
Amino acids 91–109 and 176–194 contain highly con- 
served sequences homologous to the yeast and fungal 
sterol C8–C7 isomerase. Due to their homology, these 
sequences were named steroid-binding domain-like I 
and II (SBDLI and SBDLII) ( Fig. 2 a) [39] . 
The results of epitope mapping and limited pro- 
teolysis are also consistent with the results of com- 
puter analysis of the sequence. To date, two alternative 
topological models have been proposed, differing from 
each other by the orientation of receptor insertion into 
the lipid bilayer ( Fig. 2 b and c) [16, 23] . Aydar et 
al. [23] proposed a topological model of the sigma- 
1 receptor, where two transmembrane domains of this 
receptor, TM1 and TM2, are connected in the extracel- 
lular space by a loop of about 50 amino acid residues, while its N- and C-termini are oriented towards the 
cytoplasm (see. Fig. 2 b) [23] . The C-terminal seg- 
ment extends for approximately 125 acids, and the N- 
terminal is relatively short and includes only 10 amino 
acids. 
An alternative topological model was proposed by 
Hayashi and Su; according to them, the sigma-1 recep- 
tor is localized in the ER membranes, while its N- and 
C-termini are facing the ER lumen (see. Fig. 2 c) [16] . 
A di-arginine (R7E/R8E) motif, which is a signal 
for the retention of the receptor in the ER membranes, 
is located at the N-terminal of the protein [30,40] . 
There are currently several known full-length splice 
variants of the full-length sigma-1 receptor. One of the 
forms is a variant lacking exon 3 (amino acids 119–
149) [41] . Another form that has been described is 
a truncated sigma-1 receptor the alternative splicing 
of whose mRNA results in the formation of a pre- 
mature stop codon (12-kDa variant) [42] . It is known 
that both forms are incapable of binding ligands. Their 
functional significance also remains unknown. 
It has been shown that the isolated transmembrane 
(amino acids 1–116) and C-terminal (amino acids 
116–223) receptor domains also lack the ability to 
bind ligands, even though some of the receptor’s func- 
tions are preserved (in particular, the ability to activate 
the Ins3P receptor or the chaperone activity of the 
C-terminal segment) [16, 43] . Significantly, the iso- 
lated C-terminal domain is also localized in the ER 
membranes, which is consistent with the presence of 
a third hydrophobic membrane-bound region near SB- 
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Fig. 2. Estimated structure of the sigma-1 receptor and the amino 
acid residues responsible for binding its ligands, according to data 
obtained by different methods: site-directed mutagenesis and tagging 
by photosensitive ligands (a), and also the orientation of membrane 
receptors according to epitope tagging [23] (b) and limited proteol- 
ysis [16] (c). Ext is the extracellular space; Cyto is cytoplasm; ER 
is the lumen of the endoplasmic reticulum; TM1 and TM2 are the 
highly ordered transmembrane alpha-helices; SBDLI and SBDLII 
are the steroid-binding domains I and II; ER Signal Peptide is the 
ER signaling sequence, AA-r-LB are the amino acid residues partic- 
ipating in binding the ligands of the sigma-1 receptor. The numbers 
correspond to the serial numbers of amino acid residues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DLII. NMR spectroscopy showed that residues 198–
206 correspond to this membrane-bound region [44] . 
Recently, Ortega-Roldan et al. determined the sec-
ondary structure of the sigma-1 receptor by NMR
spectroscopy [44] . The hydrophobic TM2 domain is
located around residues 91–107, whereas the amphi-
pathic membrane-bound region is within the range of
residues 198–206. The SBDLI and SBDLII segments
(see. Fig. 2 a) have been identified as alpha-helical.
The loop facing the cytosol is formed by several short
alpha-helical regions and loop sections. The same
group of authors has studied conformational changes
occurring in the C-terminal segment (amino acids
112–223) through binding to the ER chaperone proteinGRP78/BiP [38] , which have been shown to affect vir-
tually all amino acid residues of the sigma-1 receptor.
At present, it has been established through
site-directed mutagenesis, photoaffinity labeling and
molecular simulation techniques that all the domains
of a compact receptor-binding site are in one way or
another involved in its formation (see. Fig. 2 ). 
The first experiments in mapping the active site us-
ing site-directed mutagenesis allowed to identify criti-
cal residues in the second transmembrane domain for
the ligand-binding function of the receptor: S99, Y103,
L105 and L106 [45] . Using specific synthetic ligands
with photo-reactive labels, it was shown that the bind-
ing site is formed by SBDLI residues 91–109 sur-
rounding the critical nitrogen atom detected in all ago-
nists and antagonists specific for the sigma-1 receptor
[46-49] . Additionally, SBDLII amino acids 176–194
are involved in the formation of the binding site, sur-
rounding the phenyl ring of the ligand. Chen et al.
[49] described in their paper [49] the cocaine binding
site in the sigma-1 receptor and, using photosensitive
3-iodo-4-azidococaine and radiosequencing, identified
the D188 residue (located in the SBDLII region) as
one of the key amino acids involved in the formation
of a ligand-binding site. 
The C-terminal sequence 209–223 is crucial for
maintaining the structure of the active site, with its
deletions leading to loss of the ligand-binding proper-
ties [49] . 
The carboxyl terminus of the first transmembrane
domain TM1 is also involved in the formation of the
binding site through close interaction with the SBDLI
and SBDLII regions located within a distance of 8 ˚A
from each other [46,50] . Thus, the hypothetical spatial
organization of the ligand-binding site of the sigma-1
receptor is based on the intramolecular juxtaposition
of the TM1/SBDLI segments with the SBDLII region.
A recent series of papers described building a
model of the sigma-1 receptor and mapping its active
site by in silico methods and site-directed mutagenesis
[51,52] . The initial model was constructed by homol-
ogy modeling (PDB 3CIA, 1I24, 2Z2Z, 2Q8I), while
its non-homologous part (the N-terminal segment) was
constructed de novo. The computer simulation results
are in good agreement with the currently available ex-
perimental data, and the model itself has been used
to design and develop new, more specific synthetic
ligands of the sigma-1 receptor [53,54] . Mapping of
the active site allowed to identify the key residues
involved in pentazocine binding, a sigma-1 receptor
agonist. Aspartic acid residue D126 forms a crucial
connection, a salt bridge to the nitrogen atom of the
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with the hydroxyl group of the ligand; the R119, I128, 
Y173 residues form a hydrophobic pocket of the active 
site. Residue mutations in the SBDLII region had lit- 
tle effect on the binding of ligands, but the C-terminal 
segment of residues 200–223 turned out to be neces- 
sary for stabilizing the structure of the binding site. 
This model is in good agreement with the hypothesis 
about the presence of the binding site involving all of 
the receptor domains. 
There is evidence that the sigma-1 receptor is func- 
tionally active and capable of binding ligands only 
in oligomeric state [55,56] . The first macromolecular 
forms of the sigma-1 receptor (molecular masses of 
97, 130 and 147 kDa) were detected in the microso- 
mal membranes of the rat liver using radioiodinated 
photoaffinity labels [46] . Further evidence of the exis- 
tence of the sigma-1 receptor in various forms (both 
monomeric and oligomeric) was also obtained using 
spectral FRET imaging in living COS-7 cells [57] . 
In vitro experiments with the purified recombinant 
MBP-S1R fusion protein showed that only oligomeric 
forms of the sigma-1 receptor (hexamers, tetramers, 
and octamers) are capable of binding the tritiated 
agonist [3H]–( + )-pentazocine, while the monomers 
are functionally inactive [55] . Haloperidol, which is 
a well-known antagonist, promotes high-molecular 
oligomeric forms, but pentazocine, which is an ago- 
nist, stabilizes the dimers of the sigma-1 receptor [57] . 
The ability to oligomerize is associated with the 
structural features of the sigma-1 receptor. Two pre- 
sumed GxxxG dimerization motifs were found in the 
receptor sequence [56,58,59] . The first of them is lo- 
cated in the TM2 domain (residues 87–91), while the 
second one is in the C-terminal region of SBDLII 
(residues 108–112). It is possible that the first mo- 
tif mediates the dimerization of the sigma-1 receptor, 
and the other is responsible for the formation of high 
molecular weight oligomers. All point mutations in the 
oligomerization domain (GGWMG, residues 87–91) 
led to a significant decrease in the expression of the 
receptor in cells and also to a shift of the oligomeric 
forms of the receptor toward monomers [55] . The trun- 
cated form of the sigma receptor-1 (residues 1–122) 
is capable of forming heteromers with the full-length 
version of the receptor, negatively regulating the func- 
tion of the full-length version [42] . 
Chu et al. proposed a model in which the sigma-1 
receptor forms a homodimer or an oligomer containing 
dimers, with the 1:1 binding stoichiometry of ligand to 
dimer of the sigma-1 receptor [56] . In contrast with 
this model, a number of other computer simulation studies demonstrate that it is possible for ligands to 
bind to a monomeric form of the sigma-1 receptor, 
which corresponds to the stoichiometry of one ligand 
per one receptor [51–53] . 
There was an attempt to explain the physiological 
meaning of the balance between the oligomeric and 
the monomeric forms of the sigma-1 receptor by the 
hypothesis that oligomerization of the sigma-1 recep- 
tor regulates its ligand-mediated functions [57] . Pre- 
sumably, the sigma-1 receptor ligands can influence 
the kinetics of the interaction between the receptor and 
the so-called client proteins (ion channels, and others) 
by varying the ratio between the oligomeric and the 
monomeric forms and shifting the balance towards the 
former. 
To date, the sigma-1 receptor is identified as a 
highly dynamic molecule capable of forming homo- 
meric complexes for maintaining the multiple func- 
tions of the receptor. 
Further research using high-precision methods of 
structural biology, such as X-ray crystallography and 
NMR spectroscopy is necessary in order to answer the 
questions about the localization and the organization 
of the ligand-binding site more precisely, and to de- 
termine the stoichiometry for different ligands binding 
to the sigma-1 receptor. 
The role of the sigma-1 receptor in neuropathology 
Depression is known to be one of the neuropsycho- 
logical disorders, in which the sigma-1 receptor plays 
a key role. In this case, there is an observed dysfunc- 
tion of the brain structures modulated by monoamin- 
ergic systems, such as the frontal cortex and the 
hippocampus. Some antidepressants have the proper- 
ties of the sigma-1 receptor ligands, modulating many 
neurotransmitter systems, which involves the antide- 
pressant effect associated with the sigma-1 receptor. 
Indeed, the sigma-1 receptor agonists exhibit a sig- 
nificant antidepressant effect in various models [60] . 
Currently, there is evidence that these receptors affect 
mood by enhancing the serotonergic and glutamatergic 
neuronal functions, as well as due to the neurotrophic 
actions. The enhanced activation of serotonergic neu- 
rons in the dorsal raphe nucleus is an important effect 
of the sigma-1 receptor agonists. The activation of the 
serotonergic transmission under the influence of such 
agonists starts as early as after two days of treatment, 
while the clinically significant changes induced by 
the inhibition of serotonin reuptake appear only two 
or three weeks after the antidepressant administration 
started. A quick serotonergic effect of the sigma-1 
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 receptor agonists suggests an earlier onset of the
antidepressant action compared to traditional antide-
pressants. Moreover, a combination of the selective
sigma-1 receptor agonist pramipexole and the sertra-
line antidepressant in sub-effective doses exhibits a
synergistic antidepressant-like effect in an experimen-
tal model of depression [61] . In patients suffering from
depression, there is a decrease of NMDA receptors
in the prefrontal cortex and hippocampus. An exper-
imental model of depression (olfactory bulbectomy in
rats leading to a decrease in the number of NMDA
receptors) is accompanied by a behavioral deficit
resembling agitation, loss of interest and cognitive
dysfunction typical for clinical depression. The sigma-
1 receptor agonists improve the behavioral deficit and
also increase the expression of NMDA receptors.
These findings suggest a link between depression and
two types of receptors: NMDA and sigma-1 [20] . 
Along with the modulating role of the sigma-1 re-
ceptors in the glutamatergic and serotonergic trans-
mission associated with depression, they have an ad-
ditional mechanism of action related to neuroplastic
processes. The neurotrophic effect of some antidepres-
sants due to the induction of the neuronal growth fac-
tor can be regulated by the sigma-1 receptors [62] .
A high binding affinity of fluvoxamine in therapeutic
doses for the sigma-1 receptors in the brain indicates
that some effects of this antidepressant are connected
precisely with the receptors in question. 
Thus, the analysis of preclinical studies allows to
suggest possible additional clinical effects of the an-
tidepressants with the properties of the sigma-1 re-
ceptor agonists. Clinicians are focused on such phe-
nomena as the improvement of cognitive abilities, the
acceleration of the antidepressant action; the neuropro-
tective effect [63] . 
There is also data pointing to the physiological role
of the sigma-1 receptor in motor neurons. In particu-
lar, it was found that the E102Q mutation in the recep-
tor leads to an autosomal recessive form of juvenile
paralysis [64] . Motor neurons of the spinal cord die in
the course of this disease. Life expectancy is signifi-
cantly reduced in mutant mice with the deleted gene of
the sigma-1 receptor showing symptoms of paralysis,
and the paralysis symptoms occur earlier than in the
mice expressing the sigma-1 receptor. This suggests
that this receptor inhibits the development of degen-
erative processes even in mice [65] . The exact role of
the sigma-1 receptor has not yet been determined, but
different hypotheses have been proposed. 
An immunohistochemical study revealed that the
sigma-1 receptor is localized underneath the cholin-ergic boutons. It has been previously proven that two
types of potassium channels, Kv2.1 and SK are lo-
cated in the postsynaptic membrane of motoneuronal
cholinergic synapses. These channels release potas-
sium ions from cells and thus reduce motoneuronal
excitability, which is particularly important because
motor neurons are the first to die in stress conditions.
It was shown that the sigma-1 receptor ligands were
shown to affect the activity of the Kv2 and SK-type
potassium channels [21] . This regulation possibly
exists in motor neurons as well. The sigma-1 receptor
can influence potassium channels either by direct
interaction or through a chain of interacting proteins.
Thus, the sigma-1 receptor is capable of interacting
with the inositol triphosphate receptor located on the
ER membrane, while the receptor’s activators lead to a
significant increase in calcium release from the ER to
the cytosol. Calcium activates calmodulin, which, in
turn, directly activates the SK channel in the plasma
membrane. Besides, calmodulin can influence the
Kv2.1 channel by activating calcineurin, which causes
the dephosphorylation of the channel and leads to its
further activation [66] . Thus, both potassium channels
can be modulated by the activation of the sigma-1
receptor via a cascade of protein interactions. The
sigma-1 receptor also plays an important role in other
regions of the central nervous system. For example,
retinal ganglion cells were shown to die in larger
numbers when the sigma-1 receptor was knocked out
than ganglion cells of healthy animals. Mice that were
injected with amyloid peptide and thus acquired symp-
toms of Alzheimer’s disease exhibited a significantly
improved performance in memory tests [67] . Studies
using positron emission tomography showed that the
sensitivity of the sigma-1 receptors does not change in
normal aging, which contrasts with the age-dependent
decline in cholinergic, glutaminergic and dopaminer-
gic reception. However, a decrease (a loss by 26%)
in sigma-1 receptors was found in the hippocampal
CA1 region in patients suffering from Alzheimer’s
disease compared with healthy people. Moreover, this
reduction correlated with the degradation of pyramidal
neurons [68] . It has recently been discovered that
agonists of these receptors can suppress microglial
activation. As a result, the inflammatory component
of neurodegenerative diseases is reduced. 
Furthermore, recent studies have revealed the role
of impaired calcium signaling in the pathogenesis of
Alzheimer’s and Huntington’s diseases. In particular,
changes in calcium homeostasis in the ER result in
the disruption of synaptic connections in neurons
[69] . The sigma-1 receptor is assumed to act as a
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 sensor of normal calcium homeostasis. Recently, this 
receptor was also discovered to be a potential target 
for pridopidine [70] . This drug has shown some 
positive effects in the third phase of treatment of 
Huntington’s disease, and is currently assessed for 
potential use in further clinical trials [71] . Based on 
the observed effects of the drug in experiments on 
animals, pridopidine is considered by researchers as a 
dopamine ‘stabilizer’. However, the precise molecular 
mechanism of its action on the dopamine receptors is 
yet to be clarified [72] . 
Conclusion 
This review considered the specifics of the compo- 
sition and structure of the sigma-1 receptor. We dis- 
cussed possible biophysical mechanisms of the regula- 
tion of the receptor and of its involvement in various 
cellular processes, as well as its role in the devel- 
opment of various neuropathologies. Additionally, we 
have described potential applications of the sigma-1 
receptor as a therapeutic target in the treatment of this 
type of diseases. 
Given the broad opportunities for using the sigma- 
1 receptor as a protein-based therapeutic target, the 
Laboratory of Molecular Neurodegeneration (LMN) of 
the Peter the Great St. Petersburg Polytechnic Uni- 
versity is conducting comprehensive biophysical stud- 
ies on the role of the sigma-1 receptor in the context 
of neuropathological research, using such methods as 
computer modeling, X-ray crystallography, and confo- 
cal microscopy. 
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